Adero Partners’s AstraZeneca AZN Stock Holding History

Adero Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$238K	Buy	+1,621	New	+$235K	0.02%	214

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Adero Partners's AZN Position: Q1 2025 in Review

Adero Partners opened a new position in AstraZeneca (AZN) in Q1 2025: 1,621 shares worth $238K. The stake represents 0.02% of the portfolio and ranks #214 among its holdings.

1,249 funds tracked by Wall St. Rank hold AZN as of Q1 2025.

Adero Partners held 1,621 shares of AstraZeneca worth $238K as of Q1 2025.
AstraZeneca was a new Adero Partners position in Q1 2025.
AstraZeneca made up 0.02% of Adero Partners's portfolio in Q1 2025, its #214 holding.
1,249 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2025.

Based on Adero Partners's 13F filing for Q1 2025, filed 17 Apr 2025.